Randomized Phase III Trial of Avatrombopag, a Novel Oral Thrombopoietin Receptor Agonist, in Previously Treated Chronic ITP

December 9-12, 2017; Atlanta, Georgia
Cumulative duration of platelet response ≥ 50 x 109/L without rescue therapy was superior with avatrombopag vs placebo.
Format: Microsoft PowerPoint (.ppt)
File Size: 254 KB
Released: December 15, 2017

Acknowledgements

This activity is supported by educational grants from
Novartis Pharmaceuticals Corporation

Related Content

From Clinical Care Options, Zofia Piotrowska, MD, MHS, and Stephen V. Liu, MD, review key data from studies of lung cancer treatment presented at ASCO 2020

Stephen V. Liu, MD Zofia Piotrowska, MD, MHS Physicians: maximum of 1.25 AMA PRA Category 1 Credits Released: September 25, 2020 Expired: September 24, 2021

Commentary from Jeff Sharman, MD, on noncovalent BTK inhibitors in patients with CLL and progression on currently available BTK inhibitors, from Clinical Care Options (CCO)

Jeff P. Sharman, MD Released: September 25, 2020

Expert commentary featuring recommendations on preserving continuity of care and ensuring safety for patients with advanced breast cancer during the COVID-19 pandemic

Hope S. Rugo, MD Released: September 25, 2020

Gain key clinical insights fast, with this short slideset from CCO on lung cancer data presented at 2020 ASCO

Stephen V. Liu, MD Zofia Piotrowska, MD, MHS Released: September 25, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue